| Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534] | Technology appraisal guidance |
| Camlipixant for treating refractory or unexplained chronic cough [TSID12072] | Technology appraisal guidance |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888] | Technology appraisal guidance |
| Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466] | Technology appraisal guidance |
| Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214] | Technology appraisal guidance |
| Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136] | Technology appraisal guidance |
| Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099] | Technology appraisal guidance |
| Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417] | Technology appraisal guidance |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839] | Technology appraisal guidance |
| Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838] | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522] | Technology appraisal guidance |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449] | Technology appraisal guidance |
| Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [TSID10392] | Technology appraisal guidance |
| Deucravacitinib for treating active psoriatic arthritis [TSID11981] | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154] | Technology appraisal guidance |
| Digital platforms to support self-management of asthma : early value assessment | Health technology evaluation |
| Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457] | Technology appraisal guidance |
| Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521] | Technology appraisal guidance |
| Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [TSID12115] | Technology appraisal guidance |
| Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311] | Technology appraisal guidance |
| Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426] | Technology appraisal guidance |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484 | Highly specialised technology |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046] | Technology appraisal guidance |